Erba-Transasia Group Acquires Turkish IVD Company

Erba Diagnostics Mannheim, GmbH (Erba), a German subsidiary of Transasia Biomedicals (Mumbai, India)--India's leading in vitro diagnostic (IVD) company--acquired a 100% stake in Diasis Diagnostic Systems (DDS; Istanbul, Turkey).

Erba Diagnostics Mannheim and Diasis Diagnostic Systems have drawn up growth plans based on achieving economies of scale, creating synergy through intragroup coordination, widening product offering, and strengthening its after-sales service support and distribution network.

With two other strategic acquisitions, PLIVA-Lachema Diagnostika (Brno, Czech Republic) in Europe and IVAX (Miami, FL, USA) in the United States, the Erba-Transasia Group will have a direct corporate presence in USA, Italy, Czech Republic, Russia, Germany, and India. The Group already has a presence in over 50 countries through its distribution and marketing network.

Diasis Diagnostic Systems, is involved in the development, production, and marketing of products for IVD in the fields of biochemistry, hematology and urine analysis. "We regard the acquisition by Erba as a great opportunity for Diasis Diagnostic Systems to aggressively promote the full range of Erba and DDS products in Turkey, Iran, Syria, Azerbaijan and the Turkish speaking Republics," said Ruchan Ozatay, director of DDS. The company has also established an export division, which exports its manufactured reagents to several countries including Greece, Bulgaria, Pakistan, India, Bangladesh, Korea etc.

Transasia Bio-Medicals Ltd. provides total solutions for clinical diagnosis in the field of biochemistry, hematology, immunology, critical care, coagulation, and urine analysis.

Related Links:
Erba Diagnostics Mannheim, GmbH
Transasia Biomedicals
Diasis Diagnostic Systems
PLIVA-Lachema Diagnostika
IVAX